A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2026

Conditions

Acute Lymphoblastic LeukemiaNon-Hodgkin Lymphoma of Soft Tissue

Interventions

DRUG

Murine CD19 CAR-T cells

Each subject receive murine CD19 CAR T-cells by intravenous infusion

Trial Locations (1)

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER